Kornimate/medical-research-clean huggingface dataset:
virtual reality in motor neurone disease

Conditions: Motor Neuron Disease

Summary: motor neurone disease (mnd) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication. the purpose of this study is to establish if virtual reality is useful for people with mnd and if it helps improve their well being.

motor neurone disease (mnd) is a chronic progressive neurological condition where people experience weakness of muscles leading to pain and restriction of movement as well as problems with swallowing, breathing and communication. as people become increasingly immobile, they become restricted in their ability to perform activities of daily living, access the outdoors, participate in preferred occupational roles or engage in leisure activities. consequently, there is a deterioration in their ability to experience well being and have quality of life. there is also a significant carer burden as the carer spends long hours in the day looking after the person. the average disease trajectory lasts between 3-5 years, followed by death. more recently, the use of virtual reality (vr) technology is being recognised in the field of health. this technology uses the interactions between an individual and a computer generated environment to stimulate different sensory modalities such as visual and auditory. the technology can be accessed commonly using head mounted goggles or head sets. the entertaining or stimulating effect of vr is useful in redirecting the person's attention away from the distressing experiences, such as pain and anxiety. the purpose of this study is to establish if vr is useful for people with mnd and if it helps improve their well being.

Eligibility criteria:
inclusion criteria: 1. diagnosis of mnd 2. sufficient cognitive ability to understand instructions with regards using the vr kit (ecas score - minimum 100/136) 3. has sufficient motor ability/dexterity to use the kit or a carer who will be able to assist with the use of the kit. 4. can tolerate light and have sufficient head control to wear the head set. 5. english speaking exclusion criteria: 1. poor cognition - inability to understand instructions regarding the use of vr (total ecas score \<100/136) 2. unable to tolerate light/unable to wear the head set 3. light sensitive epilepsy, severe vertigo or dizziness. 4. non english speaking
effect of a single nutritional intervention previous to a critical period of fat gain in university students with overweight and obesity

Conditions: Obesity

Summary: the present study aimed to investigate the effects of a single nutritional preventive session previous to a critical period linked to fat gain in university students with overweight and obesity, emulating a nutritional session of a public health system.


Eligibility criteria:
inclusion criteria: * body mass index \[bmi\] ≥25 kg/m2 * not having metal plates * not studying nutrition and dietetics or physical education * not being pregnant exclusion criteria: - presente gastrointestinal problems (vomit or diarrheas) during the three weeks that last the experiment.
neoadjuvant therapy of pd-1 blockade combined with chemotherapy for esophageal carcinoma

Conditions: Esophageal Carcinoma; Neoadjuvant Immunotherapy

Summary: this prospective study aims to clarify the clinical efficacy and survival prognosis of neoadjuvant immune checkpoint inhibitor (ici) combined with chemotherapy for esophageal cancer. it also explores predictive biomarkers and potential therapeutic targets for locally advanced esophageal cancer based on plasma metabolomics and peripheral blood immune cell clustering analysis. each patient received 2-3 cycles of neoadjuvant immunotherapy with programmed cell death 1 (pd-1) blockade in combination with albumin paclitaxel and platinum. exploratory analysis of plasma metabolomics combined with peripheral blood subsets of immune cells can reveal biomarkers that predict the efficacy and prognosis of patients undergoing neoadjuvant immunotherapy for locally advanced esophageal cancer, which also provide new ideas for the selection of immune adjuvants and therapeutic targets in icis combination therapy strategies.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years and ≤89 years; 2. pathological histological examination confirmed the diagnosis of esophageal squamous cell carcinoma and esophageal adenocarcinoma; 3. clinical stage ii-iva; 4. adequate organ function; 5. no previous chemotherapy or radiotherapy; 6. voluntarily signed informed consent. exclusion criteria: 1. the presence of concurrent malignancies that interfere with the prognosis of esophageal cancer; 2. patients with immunodeficiency or autoimmune diseases that seriously affect the body's immune system, such as those who test positive for hiv; 3. patients undergoing systemic corticosteroid or other immunosuppressive treatments; 4. patients with a history of allergy to the components of this test drug.
prospective observational study of antitumor activity correlation between hormonal therapy and expression mirna100

Conditions: Breast Cancer

Summary: mono-centric, observational, prospective study, designed for pts with diagnosis of hormone-positive breast cancer to evaluate the correlation between the response to hormonal treatment indicated by the reduction of the level of ki67 and mirna100 in two groups of patients

the potential role of mirnas will be studied as a predictor of hormone sensitivity in hormone-positive breast carcinomas. the mirna100 obtained on biopsy will be compared with the expression levels of those obtained from the surgically removed tumor, in order to assess the possible modulation of mirna100 following hormonal treatment.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * age greater than 18 years * histological diagnosis of invasive carcinoma of the breast * x-ray evidence (mammography and / or ultrasound) strongly suggestive for the presence of invasive breast cancer (birads 4c or birads 5) of greater than 15mm diameter. * carcinoma stage i (if diameter\> 15 mm) or ii, unresectable, or * carcinoma in stage ii or iii, operable as a result of presurgical therapy, or * carcinoma in iv debut stage, asymptomatic, with primary operable breast cancer, or as a result of presurgical therapy * positivity for the estrogen receptor and / or to the progestin defined as the expression of one or both hormone receptors in ≥10% of tumor cells * negativity for her2 * cell proliferation, defined as the percentage of ki67 positive tumor cells,\> 5% (corresponding to a value of 1.79 after log-normal transformation) * postmenopausal status * ability to take an oral therapy, in the absence of malabsorption syndrome known, previous stomach surgery or the small intestine * ability to perform the staging examinations and screening provided for in the * protocol * eastern cooperative oncology group (ecog) = 0 * the patients will have a normal bone marrow function, liver and kidney exclusion criteria: * previous treatment for breast cancer with chemotherapy, lapatinib, trastuzumab, letrozole, anastrozole, exemestane or tamoxifen. * other cancers diagnosed in the last five years, with the exception of basal cell or squamous cell carcinoma of the skin, melanoma in situ or cervical cancer in situ. * premenopausal * known hypersensitivity to letrozole or to any of its excipients (for example: women with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or mal absorption of glucose / galactose). * evidence of a severe and poorly controlled systemic disease affecting the lung, heart, liver, kidney that may compromise adherence to treatment or an extended follow-up. * inflammatory bowel disease not controlled (eg crohn's disease, ulcerative colitis). * active infection and / or inadequately controlled. * alteration of mental status, dementia, or any psychiatric condition that might impair the ability to consciously sign the informed consent. * breast cancer triple negative, or negative for both her2 overexpression for the expression of hormone receptors.
imaging of injury mechanism and interaction of intestinal bacteria in children with mild traumatic brain injury

Conditions: MTBI - Mild Traumatic Brain Injury

Summary: traumatic brain injury (tbi) is the leading cause of disability in children and young adults. children with moderate to severe tbi are typically at risk of poor functional outcome in terms of neurocognitive impairment and behavior problems. neurocognitive impairments include deficits in attention and working memory, learning and memory, and executive functioning, whereas behavior problems include anxiety, depression and aggression. neuroimaging techniques based on multi-modal magnetic resonance image (mri) can detect the structural and functional brain abnormalities objectively and sensitively. recent evidence indicates that even after mild tbi, children with risk factors for intracranial pathology are at risk of poor neurocognitive and behavioral outcome.meanwhile, recently, the concept of "gut-brain axis" has been proposed and hint gut microbiota could shape the brain. some studies have emphasized that human gut microbiota plays an important role in the pathogenesis and development of tbi. however, how the gut affects the brain in patients with tbi is unclear. thus, combining analysis of neuroimaging and "gut-brain axis" will provide more information for finding the risk factors and imaging diagnostic markers of brain impairment in tbi. it will also helpful for explaining the underlying mechanisms of brain impairment in tbi, providing an objective basis for clinical diagnosis and prediction of the prognosis.


Eligibility criteria:
inclusion criteria: * age 6-14 years at time of recruitment. * hospital admission with a clinical diagnosis of tbi for inclusion in the tbi group * gcs = 15-13. * loss of consciousness duration≤30 min. * post-traumatic amnesia duration ≤1 h. exclusion criteria: * previous tbi. * visual or auditory disorder interfering with neurocognitive testing. * current neurological condition affecting the central nervous system with known effects on neurocognitive functioning, other than tbi.

Keywords: mild traumatic brain injury, mri, gut microbiota
can flaxseed prevent broken hearts in women with breast cancer study?

Conditions: Cardiotoxicity

Summary: the main goal of the current research program is to examine the use of nutraceuticals, in particular flaxseed (flx), in the prevention of doxorubicin and trastuzumab (dox+trz) mediated cardiotoxicity in the clinical setting. as manitoba continues to be one of the top flx producers in the world, there is an increasing public awareness of the importance of the consumption of this whole grain commodity in the prevention of cancer and cardiovascular disease. in north america, approximately 1 in 8 women will develop breast cancer and will receive treatment with dox+trz. although women with breast cancer are at risk of developing heart failure due to chemotherapy, flx has the capacity to prevent this outcome. the purpose of the canflax study is to establish flx "milk" as an effective method in preventing heart failure in women with breast cancer.

cardiovascular toxicity is a potential short and long-term complication of anti-cancer therapy with dox+trz in the breast cancer setting. although flx is commonly consumed in up to 30% of women with breast cancer to improve overall disease burden and survival, it is important to study whether this natural dietary agent can also reduce the cardiotoxic side effects of dox+trz in the clinical setting. the investigators hypothesize that the prophylactic consumption of flx "milk" will prevent adverse cardiovascular remodeling and improve overall functional capacity in women with breast cancer receiving dox+trz therapy. the two specific aims of the canflax study include: aim 1: flx "milk" will prevent the development of heart failure in women with early stage breast cancer (ebc) who are treated with dox+trz based chemotherapy; and aim 2: flx "milk" will improve cardiac functional capacity in this patient population.

Eligibility criteria:
inclusion criteria: * i) ≥18 years old; * ii) women with newly diagnosed early stage breast cancer (stage i-iiia) * iii) chemotherapy with 5 fluorouracil, epirubicin, and cyclophosphamide (fec) or adriamycin and cyclophosphamide (ac) for 4 months exclusion criteria: * i) pre-existing diagnosis of heart failure and/or lvef\<40% * ii) pre-existing use of anti-hypertensive agents including ace inhibitors (acei) or beta blockers * iii) planned use of any herbal/antioxidant/fatty acid/nutritional supplements at any time in the duration of the study.

Keywords: cardiotoxicity chemotherapy flaxseed
qualitative analysis of the post-stroke continuum among african stroke survivors in alabama

Conditions: Stroke; Disability Physical; Patient Satisfaction; Caregiver Burden

Summary: this proposal seeks to improve the investigators' post-stroke toc process through developing an innovative, patient informed and guided solution aimed at addressing the investigators' deep south african american population within the uab system. the investigators will engage participants in both urban and rural alabama through informational interviews and work to find common themes to address so that future interventions are useful to their unique needs and desires. this goes beyond simply identifying barriers and endeavors to discovering solutions.


Eligibility criteria:
inclusion criteria: 1. african american 2. aged 40 years and older 3. required home health therapy, outpatient therapy, skilled nursing facility or inpatient rehabilitation 4. alabama resident 5. fluent in english 6. stroke confirmed by advanced imaging (ct, mri) 7. zoom capability (participants can either have video conference ability or can call into zoom line) 8. caregivers must be identified by patients as providing a significant portion of care and/or be able to articulate their role as a caregiver exclusion criteria: 1. did not require home health therapy, outpatient therapy or inpatient rehabilitation 2. long term residents of skilled nursing facility 3. severe aphasia 4. severe cognitive impairments

Keywords: rehabilitation post-stroke rehabilitation continuum
comparison of jacobson relaxation technique and pranayama technique in patients with copd

Conditions: COPD; Shortness of Breath; Quality of Life; Cough

Summary: comparison of jacobson relaxation technique and pranayama technique in patients with copd

chronic obstructive pulmonary disease is a chronic inflammatory lung disease that cause obstructed airflow from the lungs. symptoms include breathing difficulty. cough, mucus production and wheezing. its typically caused by long term exposure to irritating gasses or particulate matter, most often from cigarette smoker. in this study we compare the effect of jacobson relaxation technique and pranayama technique on the sob, cough, sputum and quality of life in copd patients. data were collected from gulab devi chest hospital, general hospital, jinnah hospital and mayo hospital lahore. data were collected by the lottery method. borg dyspnea scale, spirometry, casa-q and quality of life questionnaire were used before and after the intervention. treatment was continuous 4 weeks, 3 times in a week for 15 mint. assessment was done through the tool before and after the treatment.

Eligibility criteria:
inclusion criteria: * • patients of age between 40 and 70. * both genders (male, female) were included. * stage 2 patient with copd with dyspnea fev1 \<70% and maximal expiratory pressure = 50% (gold criteria) were included. * cognitive stable patients were included. * those patients were included who were clinically stable without exacerbations in the past 01 month. exclusion criteria: * • common cough * upper respiratory tract inflammation * patients who have other co-morbid diseases which prevents them from exercise training, for example, disability due to neurological, orthopedic and acute cardiac causes * patients who were mentally and physically and sick to join at the hospital or research site for training * patients who were already participated or completed or in a p.r program in the past one year.

Keywords: copd jacobson technique pranayama technique sob
computerized tests of cognitive decline in presymptomatic alzheimer's disease

Conditions: Alzheimer Disease; Cognitive Decline; Aging

Summary: the investigators will study performance on computerized cognitive tasks in healthy participants of different ages to gather normative data for newly developed computerized cognitive tests. these tests are designed to permit the early detection of individuals at risk of age-related cognitive decline.

in group a, the investigators will evaluate the performance of healthy older participants (n = 300, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. the goal is to characterize changes in performance to aging and task experience in a group of older subjects. in group b, the investigators will compare the performance of normal participants (n = 100, age range 18 to 89) on computerized and manually administered cognitive tasks. in group c, the investigators will gather normative data from participants across the age range (n = 100, ages 18 to 89) for three days at enrollment, to better characterize test-retest reliability scores on day 1 tasks. in group d, the investigators will evaluate the performance of healthy older participants (n = 1200, age range 60 to 89 years) for three days at enrollment and then at 6-month intervals for three years thereafter. in the aim of better understanding health disparities in cognitive testing, this group will be divided into four cohorts: 300 african american participants; 300 asian american participants; 300 latino english-speaking participants; and 300 latino spanish-speaking participants, who will complete a spanish translation of our computerized cognitive tests.

Eligibility criteria:
inclusion criteria: * must be able to use computer mouse and touch screen * must speak english as a primary language * must speak spanish as a primary language (for latino participants completing our spanish translation) exclusion criteria: * history of psychiatric disorder * history of stroke or transient ischemic attack * history of substance abuse * history of medical or sensory disorders that are incompatible with effective testing * history of traumatic brain injury with hospitalization and extended loss of consciousness * history of epilepsy * history of depression or anxiety

Keywords: aging elderly alzheimer's disease cognition computerized testing
study assessing safety and immunogenicity of ic43 vaccination against pseudomonas aeruginosa in healthy volunteers

Conditions: Healthy

Summary: the objective is to confirm the optimal dose of ic43 in regard to immunogenicity, safety and tolerability.

the study will be designed as a multi-center, observer-blinded, randomized, placebocontrolled phase 1 study in healthy adult subjects of 18 to 65 years of age. a total of 160 healthy male and female subjects is planned to be enrolled and randomized in five groups receiving different dosages and formulations of ic43 or placebo.

Eligibility criteria:
inclusion criteria: * written informed consent obtained prior to study entry * healthy adults aged between 18 and 65 years * no clinically relevant pathological findings in any of the investigations at the screening visit. minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance * in female subjects either childbearing potential terminated by surgery or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception exclusion criteria: * history of autoimmune diseases and malignancies * active or passive vaccination 4 weeks before and during the entire study protocol * use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine * history of severe hypersensitivity reactions and anaphylaxis * known hypersensitivity or allergic reactions to one of the components of the vaccine * clinically significant diseases as judged by the investigator * immunodeficiency due to immunosuppressive therapy * a family history of congenital or hereditary immunodeficiency

Keywords: pseudomonas aeruginosa
acupuncture for low-dose opioid for tka replacement

Conditions: Knee Osteoarthritis; Pain, Postoperative; Acupuncture

Summary: the majority of patients undergoing total knee replacement(tkr) rely on opioids for postoperative analgesia. these medications have undesirable side effects and potential for abuse and addiction. the aim of this cohort study is to determine the incidence rate of patients who are able to maintain a low dose opioid regimen after tkr with the use of a multimodal approach that includes intraoperative auricular acupuncture protocol.

this is a prospective cohort study to assess the feasibility of patients to undergo tkr while adhering to a low-dose opioid regimen by using a multimodal analgesic approach that includes intraoperativeauricular acupuncture. we hypothesize that it will be feasible to maintain a low-dose opioid regimen during tkr while followingthe intraoperative auricular acupuncture protocol, and that patients will be satisfied with their pain control with a low incidence of adverse events.

Eligibility criteria:
inclusion criteria: * asa of 1 or 2 * age 18-70 * undergoing primary total knee replacement * desire to attempt a low opioid or opioid free pathway exclusion criteria: * nonenglish speaking * patients with the inability to understand or follow study protocol * opioid use in the last 6 weeks or chronic pain patient * cannot receive neuraxial anesthesia and/or peripheral nerve block * patients with contraindications to intraop protocol (e.g., patient cannot take acetaminophen or ketorolac due to liver or kidney disease) * patients with implanted cardiac device such as a pacemaker or aicd * active ear infection * nonnative ear, previous scarring or surgical manipulation of ear * patients with gauges or other deforming ear piercing (small nondeforming ear piercings are ok) present in ears * allergy to nickel

Keywords: acupuncture, total knee replacement